You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Harvard Business School
Dow
Medtronic

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

PRIALT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Prialt, and when can generic versions of Prialt launch?

Prialt is a drug marketed by Tersera Theraps Llc and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in four countries.

The generic ingredient in PRIALT is ziconotide acetate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ziconotide acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Prialt

Prialt was eligible for patent challenges on December 28, 2008.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 1, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for PRIALT
International Patents:6
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 21
Clinical Trials: 6
Drug Prices: Drug price information for PRIALT
DailyMed Link:PRIALT at DailyMed
Drug patent expirations by year for PRIALT
Drug Prices for PRIALT

See drug prices for PRIALT

Generic Entry Opportunity Date for PRIALT
Generic Entry Date for PRIALT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRATHECAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PRIALT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Albany Medical CollegePhase 4
Aaron BosterPhase 4
Jazz PharmaceuticalsN/A

See all PRIALT clinical trials

Pharmacology for PRIALT

US Patents and Regulatory Information for PRIALT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-001 Dec 28, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PRIALT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-001 Dec 28, 2004   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-004 Dec 28, 2004   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-004 Dec 28, 2004   Start Trial   Start Trial
Tersera Theraps Llc PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for PRIALT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0835126 SPC019/2005 Ireland   Start Trial SPC019/2005: 20060407, EXPIRES: 20200220
0835126 C00835126/01 Switzerland   Start Trial PRODUCT NAME: ZICONOTIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56855 11.04.2006
0835126 289 Finland   Start Trial
0835126 91181 Luxembourg   Start Trial 91181, EXPIRES: 20200221
0835126 300201 Netherlands   Start Trial 300201, 20160626, EXPIRES: 20200220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
McKinsey
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.